Vitex negundo

Vitex negundo produces iridoid glucosides (principally agnuside at ~3.04% dry weight in leaves), flavonoids (isoorientin, isovitexin, casticin), and phenolic acids (chlorogenic acid) that exert antioxidant activity via hydrogen bond donation, free radical scavenging, and molecular binding to redox-sensitive enzymes. Preclinical models demonstrate anti-inflammatory potency comparable to methylprednisolone 10 mg/kg at leaf extract doses of 9.6–28.8 g/kg body weight in murine chronic peritoneal inflammation assays, though no human randomized controlled trials have yet confirmed these effects.

Origin & History

Vitex negundo is a large aromatic shrub or small tree native to tropical and subtropical Asia, spanning India, China, the Philippines, and East Africa, typically growing in moist, well-drained soils along riverbanks and forest margins up to 1,500 m altitude. It has been cultivated for millennia across the Indian subcontinent and Southeast Asia, where its leaves, roots, and seeds are harvested seasonally for Ayurvedic and Traditional Chinese Medicine formulations. The plant thrives in warm, humid climates but tolerates periodic drought, contributing to its widespread naturalization across disturbed habitats and agricultural margins throughout South and Southeast Asia.

Historical & Cultural Context

Vitex negundo has occupied a central position in Ayurvedic medicine for over two millennia, referenced in classical texts including the Charaka Samhita and Sushruta Samhita under the Sanskrit name 'Nirgundi,' where it was prescribed for pain, inflammation, joint disorders, fever, and worm infestations. In Traditional Chinese Medicine, the plant (known as huang jing zi or man jing zi in related species contexts) was similarly employed for wind-heat conditions, headache, and eye disorders, reflecting convergent ethnopharmacological recognition across independent healing traditions. Traditional preparation methods ranged from leaf poultices applied topically for joint pain to decoctions and leaf juice consumed internally for fever reduction and anthelmintic purposes, with the aromatic volatile oil components providing characteristic bitter, pungent, and astringent organoleptic properties valued in both systems. Historical European botanical records from Portuguese and Dutch colonial natural historians in Asia during the 16th–18th centuries documented local populations using the plant's smoke for insect repellency and the root bark for snakebite management, underscoring its broad utilitarian significance across cultures.

Health Benefits

- **Antioxidant Activity**: Iridoid glucoside agnuside and flavonoids isoorientin and isovitexin scavenge reactive oxygen species and donate hydrogen atoms to stabilize free radicals; phenolic content of 2.70 mg/g in leaf extracts contributes measurable DPPH and FRAP antioxidant capacity in vitro.
- **Anti-Inflammatory Effects**: Methanolic leaf extracts at 9.6 and 28.8 g/kg body weight produced anti-inflammatory effects comparable to methylprednisolone 10 mg/kg in murine chronic peritoneal models; terpenoids and flavonoids are believed to suppress pro-inflammatory mediator synthesis.
- **Analgesic Properties**: Traditional Ayurvedic application for pain management is supported by preclinical evidence showing extract-mediated inhibition of nociceptive pathways; viridiflorol (sesquiterpenoid) and phenolic constituents are implicated in central and peripheral analgesic mechanisms.
- **Antipyretic Action**: Aqueous and methanolic leaf preparations have demonstrated fever-reducing activity in animal models, consistent with historical use for febrile conditions; flavonoid-mediated cyclooxygenase modulation is the proposed molecular basis.
- **Prolactin Regulation**: Extracts reduce serum prolactin levels in hyperprolactinemia models, paralleling the pharmacological profile of Vitex agnus-castus; this property supports traditional use for mastodynia and menstrual cycle normalization.
- **Antimicrobial and Anthelmintic Activity**: Viridiflorol and phenolic acids exhibit activity against bacterial and mycobacterial strains in vitro, while terpenoid-rich fractions demonstrate anthelmintic effects against gastrointestinal parasites in preclinical assays.
- **Antitumor Potential**: Casticin and oleanolic acid, identified in V. negundo extracts, have shown cytotoxic and apoptosis-inducing properties in cancer cell lines in vitro, though no clinical evidence currently validates antitumor efficacy in humans.

How It Works

Agnuside, the primary iridoid glucoside quantified at 3.04 ± 0.02% in dried leaves, binds target enzymes including topoisomerase via 11 hydrogen bonds alongside amide-pi stacked and pi-alkyl interactions, achieving docking scores exceeding 100 in silico, suggesting potent enzyme inhibition relevant to antioxidant and anti-inflammatory cascades. Flavonoids isoorientin, isovitexin, and scutellarin donate phenolic hydroxyl hydrogen atoms to quench reactive oxygen species and chelate transition metals, interrupting Fenton-type oxidative chain reactions. Viridiflorol, a bicyclic sesquiterpenoid, modulates pro-inflammatory cytokine production and demonstrates anti-mycobacterial membrane-disrupting activity, while casticin suppresses NF-κB signaling pathways to reduce transcription of inflammatory mediator genes. Collectively, the synergistic interaction between iridoids, flavonoids, and phenolic acids across multiple molecular targets accounts for the broad-spectrum pharmacological profile observed in preclinical models.

Scientific Research

The evidence base for Vitex negundo consists predominantly of in vitro assays and small animal model studies, with no published human randomized controlled trials identified in the available literature. GC-MS characterization studies have identified and quantified 24 volatile compounds in wild leaf extracts, and HPLC-validated methods (R²=0.9999, recovery 96.58–101.86%) have confirmed agnuside concentrations reproducibly across extraction batches, providing reliable phytochemical benchmarking. Murine anti-inflammatory experiments using doses of 9.6–28.8 g/kg body weight (leaf weight equivalents) demonstrated statistically significant reductions in chronic peritoneal inflammation markers comparable to the corticosteroid methylprednisolone at 10 mg/kg, but these extreme animal doses cannot be directly extrapolated to safe or practical human equivalents. Molecular docking and in vitro antioxidant studies support mechanistic plausibility, but the overall clinical evidence base remains at an early preclinical stage, warranting caution before drawing conclusions about human therapeutic efficacy.

Clinical Summary

No human clinical trials with defined sample sizes, randomization, or controlled endpoints have been identified for Vitex negundo or its constituent compound vitexnegheteroin in the peer-reviewed literature accessible at this time. Preclinical evidence from murine models demonstrates anti-inflammatory effects at high-dose leaf extract administration (9.6–28.8 g/kg body weight) with effect sizes comparable to methylprednisolone 10 mg/kg on peritoneal inflammation scoring metrics, though these doses are not translatable to standard human supplementation without further pharmacokinetic bridging studies. In vitro antioxidant assays confirm free radical scavenging capacity for agnuside, isoorientin, chlorogenic acid, and cynaroside, but IC50 values for iridoid glycosides exceeding 20 µM indicate moderate rather than potent antioxidant activity by contemporary benchmark standards. Confidence in clinical outcomes for humans remains low; well-designed phase I/II trials establishing safety, pharmacokinetics, and efficacious dose ranges are a prerequisite before therapeutic claims can be substantiated.

Nutritional Profile

Vitex negundo leaves contain phenolic compounds at approximately 2.70 mg/g dry weight, proteins at 2.49 mg/g, phytosterols (principally sitosterol and β-sitosterol) at 1.1 mg/g, and lipids at approximately 0.5% w/w. The dominant fatty acid identified by GC-MS is octadecadienoic acid (linoleic acid) at 21.93% of volatile extractable compounds in wild leaves, rising to 40–48% in in vitro callus cultures, accompanied by hexadecanoic acid (palmitic acid) as a secondary lipid constituent. Key bioactive phytochemicals include iridoid glucosides (agnuside at 3.04 ± 0.02% dry leaf weight; negundoside; vetugnoside), flavonoids (isoorientin, isovitexin calibration range 0.25–50 µg/mL; casticin; scutellarin; cynaroside; 5-hydroxy-7,4'-dimethoxyflavone), phenolic acids (chlorogenic acid, benzoic acid), terpenoids (viridiflorol, oleanolic acid), vitamin C, the alkaloid anhalonine, and nishindine. Bioavailability of iridoid glycosides such as agnuside is influenced by intestinal glycosidase hydrolysis liberating the aglycone, while flavonoid absorption is modulated by gut microbiota-mediated deglycosylation; no human pharmacokinetic data are currently available for these specific constituents from V. negundo.

Preparation & Dosage

- **Dried Leaf Powder (Traditional)**: Used in Ayurvedic formulations at approximately 3–6 g/day in divided doses; standardization to agnuside content (target ≥3% by HPLC) is recommended for consistency.
- **Methanolic/Hydroalcoholic Extract**: Research extracts prepared at ratios yielding agnuside concentrations comparable to the 3.04% found in dried leaves; no commercially standardized human dose has been established from clinical trials.
- **Aqueous Decoction (Traditional)**: Leaves boiled in water (10–20 g dried leaf per 500 mL) and consumed as a tea for anti-inflammatory and antipyretic purposes in Ayurvedic practice; duration traditionally 2–4 weeks for acute conditions.
- **Standardized Extract Capsules (Emerging)**: Experimental in vitro callus culture systems using BAP (2.0 mg/L) and 2,4-D (0.2 mg/L) have demonstrated enhanced bioactive yield (octadecadienoic acid up to 47.79%), suggesting potential for standardized commercial production, though no validated human supplement dose ranges are yet established.
- **Timing Note**: Traditional use typically involves morning and evening administration with food to minimize potential gastrointestinal irritation from bitter terpenoid constituents; no clinical pharmacokinetic data on optimal timing is available.
- **Important Caveat**: All dosing information above derives from traditional practice or animal model extrapolation; no evidence-based human dosing guidelines currently exist for this ingredient.

Synergy & Pairings

Vitex negundo extracts may exhibit additive or synergistic antioxidant effects when combined with vitamin C (ascorbic acid), which regenerates oxidized phenolic antioxidants back to their active reduced forms through electron transfer, potentially extending the effective antioxidant lifespan of agnuside and chlorogenic acid in biological systems. Pairing with black pepper extract standardized to piperine (5–20 mg) may enhance oral bioavailability of flavonoid glycosides such as isovitexin and casticin by inhibiting intestinal P-glycoprotein efflux and CYP3A4-mediated first-pass metabolism, a mechanism well-documented for structurally similar plant flavonoids. In traditional Ayurvedic formulations, V. negundo is frequently combined with Withania somnifera (ashwagandha) and Boswellia serrata for compounded anti-inflammatory effect, with withanolides and boswellic acids potentially addressing complementary inflammatory pathways (NF-κB and 5-LOX, respectively) alongside V. negundo's COX-modulatory and free radical scavenging actions.

Safety & Interactions

Vitex negundo has a long history of traditional use without widely reported serious adverse events, but formal toxicological profiling in humans is absent from the published literature, precluding definitive safety characterization at supplemental doses. Animal model studies employing doses as high as 9.6–28.8 g/kg body weight (leaf weight equivalent) did not report acute toxicity, but these figures represent extreme multiples of any plausible human dose and should not be interpreted as confirming safety margins for chronic human use. Given the plant's documented prolactin-lowering activity, clinically meaningful interactions with dopaminergic medications (e.g., dopamine agonists such as cabergoline or bromocriptine used in hyperprolactinemia management) and hormonal contraceptives are theoretically possible and warrant caution. The alkaloid constituent anhalonine carries psychotropic activity classification, and the anti-inflammatory potency approaching corticosteroid equivalence at high doses raises theoretical concern for immune modulation with prolonged use; use during pregnancy and lactation is not recommended due to prolactin-modulating and uterine-stimulating properties documented in traditional medicine contexts and the absence of human safety data.